Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Blood (2025) 146 (23): 2758–2764.

https://doi.org/10.1182/blood.2025028823

Published: 2025

Includes: Supplemental data

Journal Articles

The chromatin remodeler hells regulates transcription-replication conflicts and genome integrity in ALK-negative anaplastic large cell lymphoma

Selene Mallia, Giulia Gambarelli, Veronica Manicardi, Benedetta Donati, Emanuele Vitale, Federica Torricelli, Elisa Salviato, Magda Zanelli, Noemi Puccio, Stefano Luminari, Francesco Merli, Antonino Neri, Alessia Ciarrocchi, Valentina Fragliasso

Blood (2025) 146 (Supplement 1): 1477.

https://doi.org/10.1182/blood-2025-1477

Published: 2025

Journal Articles

Targeting hells‑mediated chromatin accessibility to sensitize ALK‑negative anaplastic large cell lymphoma to JAK/STAT and DNA‑PK inhibition

Giulia Gambarelli, Selene Mallia, Benedetta Donati, Noemi Puccio, Magda Zanelli, Emanuele Vitale, Federica Torricelli, Veronica Manicardi, Elisa Salviato, Stefano Luminari, Francesco Merli, Antonino Neri, Alessia Ciarrocchi, Valentina Fragliasso

Blood (2025) 146 (Supplement 1): 1476.

https://doi.org/10.1182/blood-2025-1476

Published: 2025

Journal Articles

Morphology guided spatial transcriptomics to study topography of Hodgkin reed sternberg cells interaction with tumor microenvironment and its impact in defining risk of progression in classical Hodgkin lymphoma.

Benedetta Donati, Tanja Lazic, Riccardo Valli, Rexhep Durmo, Attilio Gennaro, Cristian Ascione, Pierluigi Di Chiaro, Alessia Ruffini, Manuel Gotti, Luca Arcaini, Erica Travaglino, Marco Paulli, Francesco Merli, Alessia Ciarrocchi, Stefano Luminari

Blood (2025) 146 (Supplement 1): 5315.

https://doi.org/10.1182/blood-2025-5315

Published: 2025

Journal Articles

Impact of 1q gain/amplification in multiple myeloma patients treated with daratumumab-based regimens: A retrospective single-center study

Emiliano Barbieri, Laura Arletti, Micol Quaresima, Elena Rivolti, Luca Braglia, Monia Rinaldini, Veronica Bizzarri, Chiara Cattani, Maria Marinelli, Alessia Tieghi, Stefano Luminari, Francesco Merli, Barbara Gamberi

Blood (2025) 146 (Supplement 1): 3976.

https://doi.org/10.1182/blood-2025-3976

Published: 2025

Journal Articles

Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study FIL_RI-CHOP

Blood (2025) 146 (Supplement 1): 55.

https://doi.org/10.1182/blood-2025-55

Published: 2025

Journal Articles

Low vitamin d is an unmodifiable adverse prognostic factor in older DLBCL patients: Results from the previd randomized trial by fondazione italiana linfomi (FIL).

Blood (2025) 146 (Supplement 1): 5462.

https://doi.org/10.1182/blood-2025-5462

Published: 2025

Journal Articles

Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2024-207886

Published: 2024

Journal Articles

Transcriptomic Profiling Reveals Key Biomarkers in Primary Refractory and Early Relapse Classical Hodgkin Lymphoma

Tanja Lazic, Benedetta Donati, Maria Elena Nizzoli, Alberto Bavieri, Rexhep Durmo, Riccardo Valli, Attilio Gennaro, Cristian Ascione, Alessia Ruffini, Stefano Pozzi, Annibale Versari, Francesco Merli, Stefano Luminari, Alessia Ciarrocchi

Blood (2024) 144 (Supplement 1): 6205.

https://doi.org/10.1182/blood-2024-207696

Published: 2024

Journal Articles

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1577.

https://doi.org/10.1182/blood-2024-198076

Published: 2024

Journal Articles

Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group

Blood (2024) 144 (Supplement 1): 1663.

https://doi.org/10.1182/blood-2024-205007

Published: 2024

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 737.

https://doi.org/10.1182/blood-2023-179169

Published: 2023

Journal Articles

Development of a Novel Prognostic Score in Patients with Waldenström Macroglobulinemia Prospectively Enrolled in the Observational NF10 Study of Fondazione Italiana Linfomi

Blood (2023) 142 (Supplement 1): 3046.

https://doi.org/10.1182/blood-2023-184586

Published: 2023

Journal Articles

Rituximab and Lenalidomide (R 2 ) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 982.

https://doi.org/10.1182/blood-2023-174901

Published: 2023

Journal Articles

Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Blood (2023) 142 (17): 1438–1447.

https://doi.org/10.1182/blood.2022019173

Published: 2023

Includes: Supplemental data

Journal Articles

PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)

Blood (2022) 140 (Supplement 1): 1765–1767.

https://doi.org/10.1182/blood-2022-159759

Published: 2022

Journal Articles

Anakinra for Treatment and Prevention of CAR-T Neurotoxicity: A Systematic Review of Evidence to Inform SIE-GITMO-Sidem Guidelines

Monia Marchetti, Annalisa Chiappella, Maria Guarino, Giorgia Gobbi, Massimo Martino, Andrés J.M. Ferreri, Luca Fumagalli, Riccardo Saccardi, Mauro Montanari, Maurizio Martelli, Francesco Merli, Pier Luigi Zinzani

Blood (2022) 140 (Supplement 1): 5056–5057.

https://doi.org/10.1182/blood-2022-165125

Published: 2022

Journal Articles

Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi

Blood (2022) 140 (Supplement 1): 3603–3605.

https://doi.org/10.1182/blood-2022-166535

Published: 2022

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2021-145421

Published: 2021

Journal Articles

Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Blood (2021) 138 (Supplement 1): 2487.

https://doi.org/10.1182/blood-2021-150337

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

The chromatin remodeler hells regulates transcription-replication conflicts and genome integrity in ALK-negative anaplastic large cell lymphoma

Targeting hells‑mediated chromatin accessibility to sensitize ALK‑negative anaplastic large cell lymphoma to JAK/STAT and DNA‑PK inhibition

Morphology guided spatial transcriptomics to study topography of Hodgkin reed sternberg cells interaction with tumor microenvironment and its impact in defining risk of progression in classical Hodgkin lymphoma.

Impact of 1q gain/amplification in multiple myeloma patients treated with daratumumab-based regimens: A retrospective single-center study

Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study FIL_RI-CHOP

Low vitamin d is an unmodifiable adverse prognostic factor in older DLBCL patients: Results from the previd randomized trial by fondazione italiana linfomi (FIL).

Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi

Transcriptomic Profiling Reveals Key Biomarkers in Primary Refractory and Early Relapse Classical Hodgkin Lymphoma

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Development of a Novel Prognostic Score in Patients with Waldenström Macroglobulinemia Prospectively Enrolled in the Observational NF10 Study of Fondazione Italiana Linfomi

Rituximab and Lenalidomide (R 2 ) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)

Anakinra for Treatment and Prevention of CAR-T Neurotoxicity: A Systematic Review of Evidence to Inform SIE-GITMO-Sidem Guidelines

Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only